Pasithea Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

South san francisco, calif. and miami, april 29, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor for the treatment of neurofibromatosis type 1 (nf1) and other indications, today announced the acceptance of an abstract for poster presentation at the american society of cancer oncology (“asco”), which will be held in chicago from may 31 – june 4, 2024.

Pasithea tx (nasdaq: ktta) phase 1 trial on pas-004 for ras, nf1, and raf mutated cancers completes initial dosing, with safety data expected in 2h 2024.

-- activation of four u.s. sites for phase 1 clinical trial of pas-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- plans to open three additional sites in eastern europe in the coming months -- -- preliminary interim data expected in 2h 2024 -- south san francisco, calif. and miami, feb. 13, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced the activation of four clinical trial sites in the united states.

-- polymorph and stereoisomer patents when issued extend portfolio to at least 2045 -- -- polymorph and stereoisomer patent filings continue to expand patent portfolio -- south san francisco, calif. and miami, jan. 08, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced the invention of a crystalline form of pas-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045.

-- pas-004 is the first macrocyclic mek inhibitor to enter human clinical trials -- -- phase 1 dose escalation study in patients with mapk pathway driven advanced solid tumors to begin in q1 2024 – -- initial readout expected as early as q3 2024 – south san francisco, calif. and miami, jan. 02, 2024 (globe newswire) --   pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced the investigational new drug application (ind) clearance to proceed by the u.s. federal drug administration (fda) to evaluate pas-004, a macrocyclic mek (1/2) inhibitor, in patients with mapk pathway driven advanced solid tumors with a documented ras, raf or nf1 mutation or patients who have failed braf/mek inhibition.

Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.

Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results from PAS-004 as a treatment for lung cancer.

-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com --  PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.

Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today appeared first on InvestorPlace.

The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 25% pre-market today. This is why it happened.

Shares of penny stock KTTA are on the move and here's what's going on. The post Hot Penny Stocks Today: Why Is KTTA Stock Moving?

The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 135% pre-market today. This is why it happened.

Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric disorders, such as treatment resistant depression and post-traumatic stress disorder